PDCD1 and cancer: Persistent antigenic stimulation can lead to sustained PD-1 expression and T cell dysfunction or exhaustion.6 7 T cell exhaustion is prevalent in many cancers, and therapeutic monoclonal antibodies against PD-1 can abrogate T cell exhaustion and restore functionality.8–11